Genfit (NASDAQ:GNFT) Trading Up 2.1% - Still a Buy?

Genfit S.A. (NASDAQ:GNFT - Get Free Report) shares rose 2.1% on Monday . The company traded as high as $3.50 and last traded at $3.46. Approximately 2,869 shares traded hands during trading, a decline of 80% from the average daily volume of 14,448 shares. The stock had previously closed at $3.39.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Genfit in a research note on Friday, February 7th.

Genfit Stock Performance

The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. The stock has a fifty day moving average of $3.55 and a 200 day moving average of $4.13.

Hedge Funds Weigh In On Genfit

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC acquired a new stake in shares of Genfit S.A. (NASDAQ:GNFT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit as of its most recent SEC filing. 2.24% of the stock is currently owned by hedge funds and other institutional investors.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.